Tecentriq, Kesimpta lead latest SMC decisions
SMC was unable to accept Pfizer’s Vyndaqel for use in patients with transthyretin amyloidosis
Read More
Tag: Nilemdo
Two medicines accepted for use by NHS Scotland
Medicines for blood cancer and a rare muscle disorder will be made available for NHS patients
Read More
- Storm Therapeutics and AlidaBio launch collaboration to advance RNA‑targeting cancer therapies
- Excellence adventure
- MHRA approves Nucala for eosinophilic COPD in adults on triple therapy
- Bial launches new sublingual Parkinson’s treatment in UK
- Acesion Pharma launches phase 2 trial of AP31969 in atrial fibrillation
